WAC 246-680-010
Definitions. For the purpose of this
chapter, the following definitions apply:
(1) "Department" means the Washington state department of
health.
(2) "Health care providers" means persons licensed or
certified by the state of Washington under Title 18 RCW to
provide prenatal care or to practice medicine and qualified
genetic counselors.
(3) "Prenatal carrier testing" means a procedure to
remove blood or other tissue from one or both parents in order
to perform laboratory analysis to establish chromosome
constitution or genetic carrier status of the parents.
(4) "Prenatal test" means any test to predict congenital
or heritable disorders that may harm or endanger the health,
safety, or welfare of members of the public if improperly
utilized and includes preprocedure and postprocedure genetic
counseling, laboratory tests, and procedures as follows:
(a) Maternal serum marker screening is a procedure
involving obtaining blood from a pregnant woman during the
fifteenth to twenty-second week of gestation, in order to
measure through laboratory tests the level of certain analytes
that are associated with increased risks to the fetus or
pregnancy such as alpha-fetoprotein, unconjugated estriol,
human gonadotropin, inhibin, and/or PAPP-A.
(b) Maternal hepatitis B surface antigen (HBsAg)
screening is a procedure involving obtaining blood from a
pregnant woman during the first trimester of pregnancy to test
for maternal hepatitis B infection. HBsAg screening should be
repeated during the last trimester of pregnancy if a woman is
at high risk for hepatitis B infection.
(c) Group B strep screening per vaginorectal culture at
35-37 weeks gestation is used to screen pregnant women for
Group B strep colonization. The swab culture specimen must be
grown in selective broth media.
(d) Amniocentesis is a procedure performed after fourteen
weeks of gestation to remove a small amount of amniotic fluid
from the uterus of a pregnant woman, in order to perform one
or more of the following laboratory tests:
(i) Measure the level of alpha-fetoprotein;
(ii) Measure the level of acetylcholinesterase;
(iii) Cytogenetic studies on fetal cells including
fluorescent in-situ hybridization (FISH) if indicated;
(iv) Biochemical studies on fetal cells or amniotic
fluid;
(v) Deoxyribonucleic Acid (DNA) studies on fetal cells
including fetal genotyping for isoimmunization studies; and
(vi) Infectious disease studies.
(e) Chorionic villus sampling is a procedure performed
from ten to twelve weeks of gestation to remove a small amount
of cells from the developing placenta, in order to perform one
or more of the following laboratory tests:
(i) Cytogenetic studies on fetal cells including
fluorescent in-situ hybridization (FISH) if indicated;
(ii) Biochemical studies on fetal cells; and
(iii) DNA studies on fetal cells.
(f) Percutaneous umbilical cord blood sampling is a
procedure performed typically after fifteen weeks of gestation
to obtain blood from the fetus, in order to perform one or
more of the following laboratory tests:
(i) Cytogenetic studies including fluorescent in-situ
hybridization (FISH) if indicated;
(ii) Viral titer studies;
(iii) Fetal blood typing for isoimmunization studies;
(iv) Prenatal diagnostic tests for hematological
disorders;
(v) DNA studies on fetal cells;
(vi) Biochemical studies on fetal blood.
(g) Prenatal ultrasonography is a procedure performed at
any time during pregnancy resulting in visualization of the
uterus, the placenta, the fetus, and internal structures
through use of sound waves.
(h) "Preprocedure genetic counseling" means individual
counseling, which may be part of another procedure or service,
involving a health care provider or a qualified genetic
counselor under the direction of a physician, and a pregnant
woman with or without other family members, to assess and
identify increased risks for congenital abnormalities or
pregnancy complications, offer specific carrier or diagnostic
tests, discuss the purposes, risks, accuracy, and limitations
of a prenatal testing procedure, aid in decision making and to
assist in obtaining the desired testing or procedure.
(i) "Postprocedure genetic counseling" means, when test
results are available, individual counseling, which may be
part of another procedure or service, involving a health care
provider or a qualified genetic counselor under the direction
of a physician and a pregnant woman with or without other
family members, to discuss the results of the prenatal tests
done, any further testing or procedures available and/or
referrals for further consultation or counseling.
(j) "Qualified genetic counselor" means an individual
eligible for certification or certified as defined by the
American Board of Medical Genetics, Inc., or the American
Board of Genetic Counseling.
[Statutory Authority: RCW 48.21.244, 48.44.344, 48.46.375,
70.54.220. 03-11-031, § 246-680-010, filed 5/15/03, effective
6/15/03. Statutory Authority: RCW 43.20.050. 91-02-051
(Order 124B), recodified as § 246-680-010, filed 12/27/90,
effective 1/31/91. Statutory Authority: RCW 48.21.244,
48.44.344 and 48.46.375. 90-02-094 (Order 024), §
248-106-010, filed 1/3/90, effective 2/3/90.]